GLP-1RA for heart nerve damage in type 2 diabetes

This study tests whether a GLP-1 medication (a type of diabetes drug) can help protect nerves in the heart from damage caused by diabetes. If you have type 2 diabetes and are overweight, this trial might help researchers understand if this medication improves how your heart's nervous system works.

This study is testing whether a class of diabetes medicines called GLP-1 receptor agonists can help people with type 2 diabetes and coronary artery disease. If you have recently had a heart artery-opening procedure and are already taking another diabetes medicine called an SGLT2 inhibitor, this trial may be a good fit for you.

This trial tests whether a GLP-1 agonist (a type of diabetes medicine that also helps with weight loss) is safe and effective for people with spinal cord injury and type 2 diabetes who are not on other glucose-lowering drugs.

This study tests two different medicines (empagliflozin or semaglutide) added to your usual insulin to see if they help with blood sugar control and weight loss in people with type 1 diabetes who are overweight or have obesity. It may be a good fit if your diabetes is not well controlled with insulin injections alone.

This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.

This study tests a new medicine called NNC0487-0111 to see how well it helps people with excess body weight and type 2 diabetes lose weight, compared to another medicine called semaglutide. It may be an option if you have type 2 diabetes and are looking to manage your weight.